Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010).

Jean-François Faucher (1) , Anne-Pauline Bellanger (2, 3) , Catherine Chirouze (1) , Laurent Hustache-Mathieu (4) , Sandrine Genton (5) , Bruno Hoen (2, 6)

1 services de maladies infectieuses, CHU J Minjoz, Besançon
2 LCE - Laboratoire Chrono-environnement (UMR 6249)
3 Service de parasitologie et mycologie [CHRU de Besançon]
4 service de maladies infectieuses CHU J Minjoz Besancon
5 Pôle pharmaceutique [CHRU Besançon]
6 Service des maladies infectieuses et tropicales

Since 2008, the French guidelines have promoted the systematic use of 30 mg/day of primaquine for the radical cure of Plasmodium vivax and Plamodium ovale infections. We observed three relapses in 10 patients with P vivax acquired in French Guiana. No relapses were seen in West African P ovale patients.

Domaines: Mycologie

Jean-François Faucher, Anne-Pauline Bellanger, Catherine Chirouze, Laurent Hustache-Mathieu, Sandrine Genton, et al.. Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010).. Journal of Travel Medicine, 2013, 20 (2), pp.134-6. ⟨10.1111/jtm.12009⟩. ⟨hal-00805819⟩